Want to see ATHE full AI Analyst Report?
ATHE Stock Chart & Stats
$4.47
$0.13(2.75%)
At close: 4:00 PM EDT
$4.47
$0.13(2.75%)
Day’s Range― - ―
52-Week Range$2.35 - $5.89
Previous Close$4.56
Volume3.89K
Average Volume (3M)23.86K
Market Cap
$51.17M
Enterprise Value$19.51M
Total Cash (Recent Filing)$37.32M
Total Debt (Recent Filing)$193.47K
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Mar 04, 2027EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding19,095,903
10 Day Avg. Volume35,010
30 Day Avg. Volume23,864
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)3.19
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-169.25
Enterprise Value/Ebitda-0.69
Forecast
1Y Price Target
$13.67Price Target Upside205.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.26
Revenue Forecast (FY)$1.53M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Substantial EquityExtremely low leverage and a substantial equity base provide financial flexibility for a clinical-stage company. This reduces near-term interest burden and leaves more capacity to fund development, absorb operating volatility, and pursue strategic options while clinical programs advance.
Clearer Regulatory Path For ATH434Regulatory alignment can materially reduce development uncertainty by clarifying the evidence package required for approval. A defined Phase 3 pathway helps focus resources, supports trial planning, and improves the strategic value of ATH434 as it advances toward a pivotal study.
Long-term Patent Protection For ATH434Patent protection extending to at least 2045 strengthens the potential commercial durability of ATH434 if clinical and regulatory milestones are achieved. The protected crystalline form and treatment methods may support future partnerships and preserve strategic value across additional indications.
Bears Say
No Current Revenue And Widening LossesThe disappearance of revenue alongside widening net losses shows that Alterity has not yet established recurring operating income. Until a therapy is successfully commercialized, the company remains reliant on clinical progress and financing rather than an internally funded earnings model.
Severe And Worsening Operating Cash BurnMaterially negative operating cash flow increases the importance of runway management and future financing. Persistent burn can constrain the pace of clinical development, make capital allocation more difficult, and increase exposure to dilution or other funding requirements before revenue begins.
Equity Volatility And Funding DependenceVolatile equity levels combined with ongoing development losses indicate that funding needs may continue to shape the company’s strategy. Reliance on external capital can dilute existing holders, limit flexibility during weak financing conditions, and leave progress tied to successful capital access.
Alterity Therapeutics News
ATHE FAQ
What was Alterity Therapeutics Ltd’s price range in the past 12 months?
Alterity Therapeutics Ltd lowest stock price was $2.35 and its highest was $5.89 in the past 12 months.
What is Alterity Therapeutics Ltd’s market cap?
Alterity Therapeutics Ltd’s market cap is $51.17M.
When is Alterity Therapeutics Ltd’s upcoming earnings report date?
Alterity Therapeutics Ltd’s upcoming earnings report date is Mar 04, 2027 which is in 134 days.
How were Alterity Therapeutics Ltd’s earnings last quarter?
Alterity Therapeutics Ltd released its earnings results on Feb 25, 2026. The company reported -$0.415 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.165.
Is Alterity Therapeutics Ltd overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd’s price is currently Undervalued.
Does Alterity Therapeutics Ltd pay dividends?
Alterity Therapeutics Ltd does not currently pay dividends.
What is Alterity Therapeutics Ltd’s EPS estimate?
Alterity Therapeutics Ltd’s EPS estimate is -0.03.
How many shares outstanding does Alterity Therapeutics Ltd have?
Alterity Therapeutics Ltd has 19,095,903 shares outstanding.
What happened to Alterity Therapeutics Ltd’s price movement after its last earnings report?
Alterity Therapeutics Ltd reported an EPS of -$0.415 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went up 2.945%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd?
Currently, no hedge funds are holding shares in ATHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.67 (205.74% Upside)
$13.67 (205.74% Upside)
Insider Transactions
Bought Shares
Worth $23.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.30%
12-Months-Change
Fundamentals
Return on Equity
-48.25%
Trailing 12-Months
Asset Growth
5.70%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alterity Therapeutics Ltd
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
ATHE Stock 12 Month Forecast
Average Price Target
$13.67
▲(205.74% Upside)
Technical Analysis
Ownership Overview
1.00% Insiders
<0.01% Mutual Funds
1.05% Other Institutional Investors
97.94% Public Companies and
Individual Investors